Browse by Series:

FDA Approval and Priority Review in Ovarian Cancer, End of Part B Payment Model, and More

Gina Columbus
Published: Friday, Dec 23, 2016



Gina Columbus reports on an FDA approval and a priority review in ovarian cancer, 2 CHMP recommendations in non–small cell lung cancer, disappointing results in a prostate cancer trial, a co-branding partnership between 2 institutions, and the official demise of the Part B Payment Model.
SELECTED
LANGUAGE
Slider Left
Slider Right


Gina Columbus reports on an FDA approval and a priority review in ovarian cancer, 2 CHMP recommendations in non–small cell lung cancer, disappointing results in a prostate cancer trial, a co-branding partnership between 2 institutions, and the official demise of the Part B Payment Model.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x